Anurag K. Singh MD Professor of Oncology Director of Radiation Research Leader, Cell Stress and Biophysical Therapy Program Associate Dean Graduate Medical Education, Research Roswell Park Comprehensive Cancer Center Buffalo NY 

Early Breast Cancer: 21-Gene Recurrence Scores Can Help Guide Chemotherapy Prognosis

MedicalResearch.com Interview with:

Anurag K. Singh MD Professor of Oncology Director of Radiation Research Leader, Cell Stress and Biophysical Therapy Program Associate Dean Graduate Medical Education, Research Roswell Park Comprehensive Cancer Center Buffalo NY 

Dr. Singh

Anurag K. Singh MD
Professor of Oncology
Director of Radiation Research
Leader, Cell Stress and Biophysical Therapy Program
Associate Dean Graduate Medical Education, Research
Roswell Park Comprehensive Cancer Center
Buffalo NY

MedicalResearch.com: What is the background for this study?

Response: More than 40% of women with hormone receptor-positive, HER2-negative early stage breast cancer with high recurrence scores (RS) have RS of 26-30. Optimal adjuvant systemic therapy in this subgroup remains unclear, and national guideline currently recommends either chemoendocrine therapy or endocrine therapy alone. In addition, the difference in overall survival of a patient with a RS 26-30 versus RS >30 is unclear.  

MedicalResearch.com: What are the main findings?

Response: Our main findings are:

(1) Chemotherapy improves outcomes for those with RS 26-30,

(2) RS >30 carries a worse prognosis for survival compared to RS 26-30 despite receiving chemoendocrine therapy, and

(3) The magnitude of chemotherapy benefit appears to be similar between those with RS 26-30 and RS >30.

MedicalResearch.com: What should readers take away from your report?

Response: Breast cancer patients with a 21-gene recurrence score of 26 or higher are a heterogeneous group of patients with different prognosis and outcomes, and chemotherapy may benefit patients with recurrence scores of 26-30.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: Further prospective studies are needed to investigate optimal adjuvant therapy regimens for patients with a high 21-gene recurrence score.

Citation:

Ma SJ, Oladeru OT, Singh AK. Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher. JAMA Netw Open. 2020;3(5):e203876. doi:10.1001/jamanetworkopen.2020.3876

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

No Comments

Sorry, the comment form is closed at this time.